US14817C1071
© Globe Newswire
23.12.2025
SAVA
LISTED
NASDAQ
Cassava Announces Agreement to Settle Securities Class Action Litigation
News Preview
AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it has reached a definitive agr...
Themefolio
Profiler
Peergroup
© Globe Newswire
12.11.2025
SAVA
LISTED
NASDAQ
Cassava Reports Q3 2025 Financials Results and Provides Business Update
News Preview
AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the third qu...
Themefolio
Profiler
Peergroup
© BusinessWire
22.10.2025
SAVA
LISTED
NASDAQ
Halper Sadeh LLC Encourages Cassava Sciences, Inc. Shareholders to Contact the Firm to Discuss Their Rights
News Preview
Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders.
If you currently own Cassava stock and acquired shares on or before September 14, 2020, you may be able to seek corporate governance reforms, the return o...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© Globe Newswire
22.10.2025
SAVA
LISTED
NASDAQ
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
News Preview
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir t...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© Globe Newswire
14.08.2025
SAVA
LISTED
NASDAQ
Cassava Reports Q2 2025 Financials Results and Provides Business Update
News Preview
AUSTIN, Texas, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today reported financial results for the second quar...
Themefolio
Profiler
Peergroup
© Globe Newswire
04.08.2025
SAVA
LISTED
NASDAQ
Cassava Sciences Reports Positive Preclinical Study Evaluating Simufilam for TSC-Related Epilepsy
News Preview
AUSTIN, Texas, Aug. 04, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel treatments for central nervous system (CNS) disorders, today reported positive preclinical results of a study evaluating simufilam in a well-accepted mouse model of t...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2025
SAVA
LISTED
NASDAQ
Cassava Reports Q1 2025 Financials Results, Provides Business Update
News Preview
License agreement and recent leadership appointments position Cassava to advance development of simufilam in TSC-related epilepsy...
Themefolio
Profiler
Peergroup
© Globe Newswire
21.04.2025
SAVA
LISTED
NASDAQ
Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
News Preview
AUSTIN, Texas, April 21, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments, including simufilam, for central nervous system (CNS) disorders such as tuberous sclerosis complex (TSC)-related epilepsy, today announce...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.03.2025
SAVA
LISTED
NASDAQ
Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
News Preview
AUSTIN, Texas, March 25, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing a novel, investigational treatment for central nervous system disorders, including Alzheimer’s disease (AD) dementia and tuberous sclerosis complex (TSC)-related epilepsy,...
Themefolio
Profiler
Peergroup
© Globe Newswire
03.03.2025
SAVA
LISTED
NASDAQ
Cassava Sciences Reports 2024 Financial Results and Provides Business Update
News Preview
AUSTIN, Texas, March 03, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders, including Alzheimer’s disease and tuberous sclerosis complex (TSC)-related seizures, today rep...
Themefolio
Profiler
Peergroup
© BusinessWire
07.02.2025
SAVA
LISTED
NASDAQ
CASSAVA SCIENCES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
News Preview
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company’s securities between Febr...
Themefolio
Profiler
Peergroup
© BusinessWire
07.02.2025
SAVA
LISTED
NASDAQ
SAVA Deadline: Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action on behalf of all purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024. Cassava describes itself as a “clinical stage biotechnology company, with a focus on developing drugs for neu...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© BusinessWire
04.02.2025
SAVA
LISTED
NASDAQ
SAVA DEADLINE ALERT: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Cassava Sciences, Inc. (SAVA) Securities Fraud Class Action Lawsuit
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Peri...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.01.2025
SAVA
LISTED
NASDAQ
Cassava Sciences Provides a Business Update
News Preview
Topline data from Phase 3 REFOCUS-ALZ study of simufilam in patients with mild-to-moderate Alzheimer’s disease expected late first-quarter/early second-quarter 2025...
Themefolio
Profiler
Peergroup
© BusinessWire
27.12.2024
SAVA
LISTED
NASDAQ
SAVA Investor Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Investors of Deadline in Securities Fraud Class Action Lawsuit Filed Against Cassava Sciences, Inc.
News Preview
The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava”) (NASDAQ: SAVA) on behalf of those who purchased or otherwise acquired Cassava securities between February 7, 2024, and November 24, 2024, inclusive (the “Class Peri...
Themefolio
Profiler
Peergroup
© BusinessWire
26.12.2024
SAVA
LISTED
NASDAQ
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleg...
Themefolio
Profiler
Peergroup
© BusinessWire
18.12.2024
SAVA
LISTED
NASDAQ
SAVA INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Cassava Sciences, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
News Preview
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA) and certain of its officers.
Class Definition
This lawsuit seeks to recover damages against Defendants for alleg...
Themefolio
Profiler
Peergroup
© BusinessWire
16.12.2024
SAVA
LISTED
NASDAQ
CASSAVA SCIENCES SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Cassava Sciences, Inc. - SAVA
News Preview
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until February 10, 2025 to file lead plaintiff applications in a securities class action lawsuit against Cassava Sciences, Inc. (NasdaqCM: SAVA), if they purchased the Company’s securities between February...
Themefolio
Profiler
Peergroup
© BusinessWire
13.12.2024
SAVA
LISTED
NASDAQ
Rosen Law Firm Urges Cassava Sciences, Inc. (NASDAQ: SAVA) Stockholders with Large Losses in Excess of $100K to Contact the Firm for Information About Their Rights
News Preview
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Cassava Sciences, Inc. (NASDAQ: SAVA) between February 7, 2024 and November 24, 2024. Cassava describes itself as a “clinical stage biotechnology company, with a focus on developing drugs for neurodegene...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.11.2024
SAVA
LISTED
NASDAQ
Cassava Sciences to Hold Corporate Update on November 25th
News Preview
Webcast planned for Monday, November 25th at 8:00 AM ET Webcast planned for Monday, November 25th at 8:00 AM ET...
Themefolio
Profiler
Peergroup
© Globe Newswire
07.11.2024
SAVA
LISTED
NASDAQ
Cassava Sciences Reports Q3 2024 Financial and Operating Results
News Preview
AUSTIN, Texas, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on developing a novel treatment for Alzheimer’s disease, today reported financial results for the third quarter ended September 30, 2024....
Themefolio
Profiler
Peergroup
© Globe Newswire
26.09.2024
SAVA
LISTED
NASDAQ
Cassava Sciences Resolves SEC Investigation
News Preview
AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced that it has reached a settlement with the U.S. Securities and Exchange Commission (“SEC”) of negligence-based disclosure charges that resolve a previously-dis...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.08.2024
SAVA
LISTED
NASDAQ
Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates
News Preview
AUSTIN, Texas, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on a novel treatment for Alzheimer’s disease, today reported financial results for the second quarter ended June 30, 2024. Net income was $6.2 million compared to a net loss of $26.4 million for the same period in 2023. Net cas...
Themefolio
Profiler
Peergroup
© Globe Newswire
05.08.2024
SAVA
LISTED
NASDAQ
Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson
News Preview
AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the passing of long-time board member Sanford Robertson....
Themefolio
Profiler
Peergroup
© Globe Newswire
30.07.2024
SAVA
LISTED
NASDAQ
Cassava Sciences Announces Expansion of Open-Label Extension Trials
News Preview
AUSTIN, Texas, July 30, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Company will extend by up to an additional 36 months each of the open-label extension trials in its ongoing Phase 2 and Phase 3 clinical programs. These amendments to the protocols will allow patients who have previously participated in...
Themefolio
Profiler
Peergroup
© Globe Newswire
17.07.2024
SAVA
LISTED
NASDAQ
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
News Preview
AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Board of Directors has appointed Richard (Rick) Barry as Executive Chairman of the Board and as the Company’s principal executive officer, effective immediately. The Company is undertaking a search for a new permanent CEO....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.06.2024
SAVA
LISTED
NASDAQ
Cassava Sciences Issues Statement on Former Science Advisor
News Preview
AUSTIN, Texas, June 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), reported it has learned today that a federal grand jury returned an indictment charging Hoau-Yan Wang for allegedly defrauding the U.S. National Institutes of Health (NIH). Hoau-Yan Wang was a tenured medical professor at a public university’s medical school a...
Themefolio
Profiler
Peergroup
© Globe Newswire
10.05.2024
SAVA
LISTED
NASDAQ
Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam
News Preview
AUSTIN, Texas, May 10, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial results for first quarter ended March 31, 2024. Net income was $25.0 million compared to a net loss of $24.3 million for the same period in 2023. Net cash used in operations was $1...
Themefolio
Profiler
Peergroup
© Globe Newswire
08.05.2024
SAVA
LISTED
NASDAQ
Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution
News Preview
Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per Share Gross Proceeds from Warrants Represents the Sale of Approximately 5.7 Million Shares Of Common Stock At $22.00 Per Share...
Themefolio
Profiler
Peergroup
© Globe Newswire
01.05.2024
SAVA
LISTED
NASDAQ
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
News Preview
AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA) (“Cassava Sciences” or the "Company") has been advised by NASDAQ that end-of-day (“EOD”) tomorrow May 2, 2024, will be the last and final trading day for SAVAW warrants on NASDAQ. After EOD May 2, the Company expects NASDAQ to no longer accept or execute any tra...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
